Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.25)
# 348
Out of 5,182 analysts
142
Total ratings
52.24%
Success rate
14.42%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $8 → $10 | $3.48 | +187.36% | 8 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $135 → $140 | $102.25 | +36.92% | 2 | Feb 27, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $150 → $100 | $14.93 | +569.79% | 8 | Feb 27, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $130 | $95.65 | +35.91% | 7 | Dec 8, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $6.55 | +281.68% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $120.03 | +66.63% | 1 | Nov 6, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $3.07 | +877.20% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $71.93 | +52.93% | 13 | Oct 30, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $1.29 | +675.19% | 1 | Oct 6, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $69.81 | +7.43% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.41 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $24.84 | +0.64% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $13.10 | +90.84% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $5.54 | +8.30% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $220.48 | +27.00% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $4.04 | +1,137.62% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $6.67 | +199.85% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $263.99 | -18.56% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.67 | +87.27% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.65 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $8.15 | +268.10% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.24 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.47 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $38.41 | +134.31% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.67 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $163.03 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $61.18 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.51 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.99 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $114.80 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $8.05 | +1,390.68% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $57.65 | +12.75% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $17.06 | -35.52% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $130.90 | -0.69% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $760.27 | -0.04% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $26.00 | -42.31% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $14.86 | +270.12% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.72 | +1,644.19% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.14 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.80 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $511.89 | -51.16% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $93.69 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $73.89 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.96 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $17.14 | +28.35% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $16.56 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $56.22 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $206.37 | -53.97% | 1 | Aug 17, 2017 |
Rocket Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $10
Current: $3.48
Upside: +187.36%
Nuvalent
Feb 27, 2026
Maintains: Overweight
Price Target: $135 → $140
Current: $102.25
Upside: +36.92%
Janux Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $150 → $100
Current: $14.93
Upside: +569.79%
Mirum Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $95 → $130
Current: $95.65
Upside: +35.91%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $6.55
Upside: +281.68%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $120.03
Upside: +66.63%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $3.07
Upside: +877.20%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $71.93
Upside: +52.93%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $1.29
Upside: +675.19%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $69.81
Upside: +7.43%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $19.41
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $24.84
Upside: +0.64%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $13.10
Upside: +90.84%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $5.54
Upside: +8.30%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $220.48
Upside: +27.00%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $4.04
Upside: +1,137.62%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $6.67
Upside: +199.85%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $263.99
Upside: -18.56%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.67
Upside: +87.27%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.65
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $8.15
Upside: +268.10%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.24
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.47
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $38.41
Upside: +134.31%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.67
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $163.03
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $61.18
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.51
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.99
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $114.80
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $120
Current: $8.05
Upside: +1,390.68%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $57.65
Upside: +12.75%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $17.06
Upside: -35.52%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $130.90
Upside: -0.69%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $760.27
Upside: -0.04%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $26.00
Upside: -42.31%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $14.86
Upside: +270.12%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.72
Upside: +1,644.19%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.14
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $8.80
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $511.89
Upside: -51.16%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $93.69
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $73.89
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.96
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $17.14
Upside: +28.35%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $16.56
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $56.22
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $206.37
Upside: -53.97%